Hcw Biologics Inc (HCWB)

$3.00 +0.51 (20.48%)
Market Cap 5.36M
Revenue (ttm) 2.57M
Net Income (ttm) -30.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,168.09%
Debt to Equity Ratio -135.80
Volume 1,728,100
Avg Vol 596,112
Day's Range N/A - N/A
Shares Out 2.15M
Stochastic %K 47%
Beta 0.63
Analysts Strong Sell
Price Target $35.00

Company Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is i...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 842 2024
Fax: 954 842 2037
Address:
2929 North Commerce Parkway, Miramar, United States
makedatbread88
makedatbread88 Nov. 14 at 8:39 PM
$HCWB VERY weird price action on this ticker today Ran to $3.50 then down to $2.38 now right back to $3.10
1 · Reply
KannyBuffett
KannyBuffett Nov. 14 at 6:10 PM
$HCWB
0 · Reply
chrisusm
chrisusm Nov. 14 at 4:43 PM
$HCWB in 2.50
0 · Reply
dixiebull
dixiebull Nov. 14 at 4:31 PM
still watching this $HCWB to bust that 3
0 · Reply
KannyBuffett
KannyBuffett Nov. 14 at 4:08 PM
$HCWB $LLY
0 · Reply
KannyBuffett
KannyBuffett Nov. 14 at 3:43 PM
$HCWB buyout? After hour?
1 · Reply
_www_larval_com_
_www_larval_com_ Nov. 14 at 3:37 PM
$HCWB has reverted -6% lower to 7% (~1Mv) a moment ago, follow for more volatility.
0 · Reply
Waheedhamed0303
Waheedhamed0303 Nov. 14 at 3:35 PM
$HCWB bear trap, my friend
0 · Reply
mrtradez
mrtradez Nov. 14 at 3:30 PM
$HCWB #symbolalerts Short
0 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:30 PM
$HCWB would of been a good short. Too busy stuffing sausage egg and cheese croissant in my face
0 · Reply
Latest News on HCWB
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 14, 2025, 4:44 PM EST - 11 hours ago

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 7, 2025, 7:00 AM EST - 7 days ago

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

HCW Biologics to Participate in the 2025 Maxim Growth Summit

Oct 16, 2025, 9:25 AM EDT - 4 weeks ago

HCW Biologics to Participate in the 2025 Maxim Growth Summit

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Sep 30, 2025, 8:45 AM EDT - 6 weeks ago

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Sep 18, 2025, 9:15 AM EDT - 2 months ago

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Sep 16, 2025, 8:00 AM EDT - 2 months ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

Aug 25, 2025, 9:53 AM EDT - 2 months ago

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Aug 25, 2025, 8:00 AM EDT - 2 months ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 18, 2025, 2:44 PM EDT - 3 months ago

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Jun 27, 2025, 7:45 AM EDT - 5 months ago

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

Jun 26, 2025, 7:55 AM EDT - 5 months ago

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

Jun 4, 2025, 8:20 AM EDT - 5 months ago

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

May 15, 2025, 6:14 PM EDT - 6 months ago

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

May 13, 2025, 8:01 PM EDT - 6 months ago

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

May 13, 2025, 8:30 AM EDT - 6 months ago

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

HCW Biologics Announces 1-for-40 Reverse Stock Split

Apr 1, 2025, 4:35 PM EDT - 8 months ago

HCW Biologics Announces 1-for-40 Reverse Stock Split

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Mar 28, 2025, 3:30 PM EDT - 8 months ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

Mar 6, 2025, 6:55 AM EST - 9 months ago

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Feb 3, 2025, 7:15 AM EST - 10 months ago

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Jan 15, 2025, 7:00 AM EST - 10 months ago

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Dec 23, 2024, 8:10 AM EST - 11 months ago

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Nov 18, 2024, 9:27 PM EST - 1 year ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Why Is Penny Stock HCW Biologics Surging On Monday?

Nov 18, 2024, 10:15 AM EST - 1 year ago

Why Is Penny Stock HCW Biologics Surging On Monday?

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

Nov 18, 2024, 7:00 AM EST - 1 year ago

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 14, 2024, 4:40 PM EST - 1 year ago

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Aug 23, 2024, 4:30 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 14, 2024, 4:35 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

May 15, 2024, 4:39 PM EDT - 1 year ago

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Apr 1, 2024, 4:10 PM EDT - 1 year ago

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Nov 14, 2023, 7:00 AM EST - 2 years ago

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Nov 8, 2023, 7:30 AM EST - 2 years ago

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Sep 6, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Jun 14, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

May 9, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Apr 27, 2023, 7:40 AM EDT - 2 years ago

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

Apr 13, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

Apr 3, 2023, 8:13 AM EDT - 2 years ago

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 28, 2023, 4:25 PM EDT - 2 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

HCW Biologics Enters CRADA with National Cancer Institute

Dec 8, 2022, 7:55 AM EST - 3 years ago

HCW Biologics Enters CRADA with National Cancer Institute

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Dec 7, 2022, 7:30 AM EST - 3 years ago

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

Nov 8, 2022, 7:00 AM EST - 3 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

Nov 7, 2022, 4:45 PM EST - 3 years ago

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

Aug 31, 2022, 9:22 AM EDT - 3 years ago

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

SMSI

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

Aug 29, 2022, 8:58 AM EDT - 3 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

CASI HSDT

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

Aug 12, 2022, 7:00 AM EDT - 3 years ago

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

Aug 3, 2022, 7:15 AM EDT - 3 years ago

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

May 23, 2022, 7:30 AM EDT - 3 years ago

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 13, 2022, 7:15 AM EDT - 3 years ago

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

makedatbread88
makedatbread88 Nov. 14 at 8:39 PM
$HCWB VERY weird price action on this ticker today Ran to $3.50 then down to $2.38 now right back to $3.10
1 · Reply
KannyBuffett
KannyBuffett Nov. 14 at 6:10 PM
$HCWB
0 · Reply
chrisusm
chrisusm Nov. 14 at 4:43 PM
$HCWB in 2.50
0 · Reply
dixiebull
dixiebull Nov. 14 at 4:31 PM
still watching this $HCWB to bust that 3
0 · Reply
KannyBuffett
KannyBuffett Nov. 14 at 4:08 PM
$HCWB $LLY
0 · Reply
KannyBuffett
KannyBuffett Nov. 14 at 3:43 PM
$HCWB buyout? After hour?
1 · Reply
_www_larval_com_
_www_larval_com_ Nov. 14 at 3:37 PM
$HCWB has reverted -6% lower to 7% (~1Mv) a moment ago, follow for more volatility.
0 · Reply
Waheedhamed0303
Waheedhamed0303 Nov. 14 at 3:35 PM
$HCWB bear trap, my friend
0 · Reply
mrtradez
mrtradez Nov. 14 at 3:30 PM
$HCWB #symbolalerts Short
0 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:30 PM
$HCWB would of been a good short. Too busy stuffing sausage egg and cheese croissant in my face
0 · Reply
IBOTTheDipAndTheDipWon
IBOTTheDipAndTheDipWon Nov. 14 at 3:23 PM
$HCWB The big red candles appeared sooner than I expected so I was late to the party but I had a reasonable short w/ 8% profit.
1 · Reply
KannyBuffett
KannyBuffett Nov. 14 at 3:23 PM
$HCWB news leaked
0 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:22 PM
$HCWB 😂you ever grab your breakfast sandwich out the microwave and just so happen to pull it out right where the hole is and that burning hot steam hits your finger.. yeh that's what this felt like after the halt. Lost that damn profit. If it doesn't want to climb back up we'll just cut that bit of profit right out the daily p&l and move tf on 🫡
0 · Reply
DaSqueeza
DaSqueeza Nov. 14 at 3:21 PM
$HCWB welcome new bagholders
1 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:15 PM
$HCWB I sold before the halt
0 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:15 PM
$HCWB haha dang man that ended quick
0 · Reply
Stockchef84
Stockchef84 Nov. 14 at 3:15 PM
$HCWB wow.... i made a mistake
0 · Reply
chadAbu1
chadAbu1 Nov. 14 at 3:13 PM
$HCWB what’s going on here?
0 · Reply
DaBullRunner
DaBullRunner Nov. 14 at 3:13 PM
$CYCU another BANGER from the $2’s👇💰💰💰💰 🚨TGL🚨 adding on that MONSTER news I’m even willing to put some of my COIN TSLA profits into SDA $AMZE $BYND $CYPH $HCWB lets get it
0 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:12 PM
$HCWB still halted up bullish
0 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:11 PM
$NUAI $DVLT y'all see $HCWB ?!
1 · Reply
DylanGFM
DylanGFM Nov. 14 at 3:11 PM
$HCWB $CYCU
0 · Reply